Ambarish Pandey, MD
Cardiovascular Disease · Dallas, TXNPI 1891084729
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $210,193 of the $324,852 with a category attached, or 64.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 12.7%. 2025 is the largest year on record at $161,538, 4.0 times the $40,717 reported in 2022. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $1418.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$41K
- Bayer$36K
- Novo Nordisk$34K
- Roche Diagnostics International Ltd$33K
- Eli Lilly$31K
- Roche Diagnostics Corporation$30K
- plus $119K from 19 others
Across 834 payments — averaging $3591.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$1.2M
- Applied Therapeutics, Inc.$771K
- Scpharmaceuticals Inc.$277K
- E.r. Squibb & Sons, L.L.C.$163K
- Boehringer Ingelheim International GmbH$158K
- Novo Nordisk AS$148K
- plus $274K from 7 others
What the payments were for
- Consulting fees$210,19365%
- Speaking & faculty fees$45,44814%
- Travel & lodging$62,51319%
- Food & beverage$6,6982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 8 | $41,312 |
| Bayer | 30 | $36,480 |
| Novo Nordisk | 21 | $33,908 |
| Roche Diagnostics International Ltd | 10 | $32,882 |
| Eli Lilly | 51 | $30,650 |
| Roche Diagnostics Corporation | 16 | $30,240 |
| Pfizer | 12 | $23,974 |
| Boehringer Ingelheim | 21 | $23,913 |
| Alnylam Pharmaceuticals Inc. | 11 | $15,507 |
| Abbott | 7 | $10,134 |
| Merck | 5 | $8,425 |
| Edwards Lifesciences | 5 | $8,084 |
| AstraZeneca | 11 | $7,217 |
| Idorsia Pharmaceuticals US Inc | 1 | $6,440 |
| Kilele Health Inc | 1 | $5,000 |
| Medtronic | 9 | $4,861 |
| Novartis | 1 | $2,400 |
| Scpharmaceuticals Inc. | 2 | $2,126 |
| Altathera Pharmaceuticals LLC | 1 | $600 |
| E.r. Squibb & Sons, L.L.C. | 1 | $267 |
| Roche Diabetes Care, Inc. | 1 | $141 |
| Anumana, Inc. | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $98 |
| Esperion Therapeutics, Inc. | 1 | $52 |
| Mindray DS USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$34,236
- STEGLATRO$22,894
- JARDIANCE$17,801
- Alinity$10,125
- Tryvio$6,440
- Elecsys Troponin T Gen 5 STAT$3,156
- cobas 8000 Core Unit$2,885
- FUROSCIX$2,100
- Sotalol Hydrochloride$600
- ECG-AI LEF$125
How this compares
$324,852 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $97,673 |
| FuroscixFurosemide | 13 | $87,261 |
| OzempicSemaglutide | 83 | $76,707 |
| EntrestoSacubitril/Valsartan | 83 | $63,438 |
| MounjaroTirzepatide | 24 | $32,778 |
| FarxigaDapagliflozin Propanediol | 23 | $19,398 |
| KerendiaFinerenone | 16 | $11,019 |
| RybelsusSemaglutide | 12 | $10,895 |
| Torsemide | 97 | $3,310 |
| Potassium Chloride | 35 | $835 |
| Spironolactone | 129 | $719 |
| Carvedilol | 74 | $471 |
| Metoprolol Succinate | 39 | $371 |
| Furosemide | 79 | $317 |
| Losartan Potassium | 20 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $23,913 | $97,673127 claims |
| Novo NordiskOzempic, Rybelsus | $33,908 | $87,60295 claims |
| Scpharmaceuticals Inc.Furoscix | $2,126 | $87,26113 claims |
| NovartisEntresto | $2,400 | $63,43883 claims |
| AstraZenecaFarxiga | $7,217 | $19,39823 claims |
| BayerKerendia | $36,480 | $11,01916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
- Subhash BanerjeeDallas$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.